You are viewing an expired study

This study is not currently recruiting Study Participants on If you would like to find active studies please browse nearby listings below.

Click here to view additional nearby studies or search for clinical trials.

Charlottesville, Virginia 22903

  • Menopause


The purpose of this study is to determine whether a pulsed magnetic field (PMF) pad will improve symptoms of rheumatoid arthritis (RA) in postmenopausal women. Study hypothesis: A pulsed magnetic field pad will effectively reduce the symptoms of RA in postmenopausal women.

Study summary:

RA is a condition characterized by pain, fatigue, sleep disturbances, and mood changes. These symptoms often persist despite the use of nonsteroidal anti-inflammatory drugs (NSAIDs) and disease modifying antirheumatic drugs (DMARDs). Many women for whom these drugs do not work turn to complementary and alternative therapies, including the use of magnetic devices. Although few studies have investigated the effects of low strength PMF pads in persons with RA, evidence suggests that PMF may help relieve pain, inflammation, and fatigue. This study will determine the effects of a PMF device on RA symptoms in postmenopausal women. This study will last 12 weeks. Participants will be randomly assigned to one of three groups: active PMF pad treatment, sham PMF pad treatment, or standard of care, which may include drug therapy or physical therapy. Participants in the active and sham PMF pad groups will be treated with their assigned pad for approximately 8 minutes, twice a day for the duration of the study. Questionnaires and self-report scales will be used to assess pain, fatigue, sleep quality, mood, and inflammation episodes. Blood and urine collection will occur to assess levels of stress hormones and certain proteins.


Inclusion Criteria: - Diagnosis of RA - Postmenopausal, defined by no menstrual period in at least 2 years prior to study entry or a hysterectomy - Average pain of 2 or greater on a 0 to 10 pain scale - Sleep difficulty - Stable medication use related to RA for at least 4 weeks prior to study entry Exclusion Criteria: - Diagnoses of lupus, sleep apnea, or restless leg syndrome - High-dose prednisone (more than 10 mg/day) or equivalent - Pacemakers or other implanted devices - Epilepsy - Currently undergoing treatment for cancer



Primary Contact:

Principal Investigator
Cheryl M. Bourguignon, PhD, RN
University of Virginia

Backup Contact:


Location Contact:

Charlottesville, Virginia 22903
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: March 26, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.